Underutilization of Lynch syndrome screening in a multisite study of patients with colorectal cancer

Genetics in Medicine

Volumn 15, Issue 12, 2013, Pages 933-940

  Cross, Deanna S ^a   Rahm, Alanna Kulchak ^b   Kauffman, Tia L ^c   Webster, Jennifer ^c   Le, Anh Quynh ^b   Spencer Feigelson, Heather ^b   Alexander, Gwen ^d   Meier, Paul ^d   Onitilo, Adedayo A ^a   Pawloski, Pamala A ^e   Williams, Andrew E ^b   Honda, Stacey ^b   Daida, YeeHwa ^b   Mccarty, Catherine A ^f   Goddard, Katrina A B ^c  

^a MARSHFIELD CLINIC   (United States)

^b KAISER PERMANENTE   (United States)

^c CENTER FOR HEALTH RESEARCH   (United States)

^d HENRY FORD HEALTH SYSTEM   (United States)

^e Health Partners Institute for Education and Research   (United States)

^f ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

Author keywords

family history; genetic testing; hereditary cancer screening; Lynch syndrome; metastatic colorectal cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER SCREENING; FAMILY HISTORY; FEMALE; HEALTH CARE UTILIZATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTEGRATED HEALTH CARE SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; ONSET AGE; PRACTICE GUIDELINE;

AGED; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DATA COLLECTION; DELIVERY OF HEALTH CARE; FAMILY HEALTH; FEMALE; GENETIC TESTING; HUMANS; MALE; MEDICAL HISTORY TAKING; MEDICAL RECORDS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PRACTICE GUIDELINES AS TOPIC;

EID: 84890033683     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.43     Document Type: Article

References (38)

1. American Cancer Society. Cancer facts and figures 2012. http://www.cancer. org/acs/groups/content/@epidemiologysurveilance/documents/ document/ acspc-031941 pdf. Accessed 29 July 2012
2. US Cancer Statistics Working Group, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Cancer Institute. United States Cancer Statistics: 1999-2008 incidence and mortality web-based report, 2012 update. http://apps.nccd.cdc.gov/uscs. Accessed 19 December 2012
3. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860
4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-932
5. Weissman SM, Burt R, Church J, et al. Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline. J Genet Couns 2012;21:484-493
6. Weissman SM, Bellcross C, Bittner CC, et al. Genetic counseling considerations in the evaluation of families for Lynch syndrome-A review. J Genet Couns 2011;20:5-19
7. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: Genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41
8. Win AK, Young JP, Lindor NM, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: A prospective cohort study. J Clin Oncol 2012;30:958-964
9. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268
10. Bonadona V, Bonaïti B, Olschwang S, et al.; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;305:2304-2310
11. Bellcross CA, Bedrosian SR, Daniels E, et al. Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: Summary of a public health/clinical collaborative meeting. Genet Med 2012;14: 152-162
12. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM; American College of Gastroenterology. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750
13. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Colorectal cancer screening version 3.2012. http://www.ncc. org. Accessed 2 August 2012
14. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA 2006;296:1507-1517
15. Guastadisegni C, Colafranceschi M, Ottini L, Dogliotti E. Microsatellite instability as a marker of prognosis and response to therapy: A meta-Analysis of colorectal cancer survival data. Eur J Cancer 2010;46:2788-2798
16. Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011;103:863-875
17. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-Analysis. Eur J Cancer 2009;45:1890-1896
18. Mvundura M, Grosse SD, Hampel H, Palomaki GE. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. Genet Med 2010;12:93-104
19. Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Ann Intern Med 2011;155:69-79
20. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med 2009;11:42-65
21. Levin B, Lieberman DA, McFarland B, et al.; American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-1595
22. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116:1453-1456
23. The HMO Cancer Research Network. The HMO Cancer Research Network: Capacity, Collaboration, & Investigation. NIH Publication No. 10-6448 ed. US Department of Health and Human Services: Washington, DC, 2010
24. Webster J, Kauffman TL, Feigelson HS, et al.; CERGEN study team. KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev 2013;22:91-101
25. Hornbrook MC, Hart G, Ellis JL, et al. Building a virtual cancer research organization. J Natl Cancer Inst Monographs 2005;35:12-25
26. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006;354:2751-2763
27. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81
28. Wood M, Kadlubek P, Lu KH et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: A pilot test of quality measures as part of the ASCO Quality Oncology Practice Initiative (QOPI) [abstract]. J Clin Oncol 2012;30:Abstr CRA1505
29. Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol 2004;2:813-819
30. Murff HJ, Greevy RA, Syngal S. The comprehensiveness of family cancer history assessments in primary care. Community Genet 2007;10:174-180
31. van Dijk DA, Oostindiër MJ, Kloosterman-Boele WM, Krijnen P, Vasen HF; Hereditary Tumor Study Group of the Comprehensive Cancer Centre West. Family history is neglected in the work-up of patients with colorectal cancer: A quality assessment using cancer registry data. Fam Cancer 2007;6: 131-134
32. Mukherjee A, McGarrity TJ, Ruggiero F, et al. The revised Bethesda guidelines: Extent of utilization in a university hospital medical center with a cancer genetics program. Hered Cancer Clin Pract 2010;8:9
33. Singh H, Nugent Z, Demers AA, Bernstein CN. Rate and predictors of early/ missed colorectal cancers after colonoscopy in Manitoba: A population-based study. Am J Gastroenterol 2010;105:2588-2596
34. Tranø G, Wasmuth HH, Sjursen W, Hofsli E, Vatten LJ. Awareness of heredity in colorectal cancer patients is insufficient among clinicians: A Norwegian population-based study. Colorectal Dis 2009;11:456-461
35. Van Lier MG, De Wilt JH, Wagemakers JJ, et al. Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome. Scand J Gastroenterol 2009;44: 600-604
36. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. J Clin Oncol 2012;30:1058-1063
37. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008;26: 5783-5788
38. Moreira L, Balaguer F, Lindor N, et al.; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 2012;308: 1555-1565